Jointly sponsored by the University of Cincinnati and Princeton CME
Target Audience
This activity is designed for hospital-based physicians, including cardiologists, hematologists, and oncologists, and pharmacists.
Learning Objectives
After completing this activity, participants should be able to:
- Describe frequent comorbidities that increase venous thromboembolism (VTE) risk and complicate antithrombin use in VTE prevention and management
- Summarize recent guidelines for diagnosis, prevention, and treatment of VTE in cancer patients
- Apply the latest evidence to ensure appropriate antithrombin dosing for obese patients
- State the challenges with antithrombin therapy and strategies for VTE prevention and management in patients with renal insufficiency
Credit Eligibility
To be eligible for documentation of credit, all participants must participate in the full educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit. Those who mail or fax back their successfully completed post-test and evaluation form will receive documentation of credit by mail within 6 weeks.
Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.
Release date: November 29, 2007; Expiration date: November 29, 2008.
Estimated time to complete: 1 hour
There is no fee associated with this activity.
Lecture Components
The presentation slides, post-test, and evaluation are available as a click through via the menu at the top of each page of this educational activity.
CME Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Cincinnati and Princeton CME. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of theirparticipation in the activity.
CPE Accreditation
Princeton CME is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (ACPE Provider #452) and complies with the Criteria for Quality and Interpretive Guidelines. This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UPN 452-999-07-015-H01).
Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity sponsored or cosponsored by Princeton CME may contact the Assistant Director of Continuing Education in writing. The Assistant Director of Continuing Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Director of Continuing Education may be made for a second level of review.
Grant Support
Supported by an educational grant from sanofi-aventis U.S.
Presenter
Geno J. Merli, MD, FACP
Chief Medical Officer
Senior Vice President for Clinical Affairs
Thomas Jefferson University Hospital, Inc
Professor of Medicine
Jefferson Center for Vascular Diseases
Jefferson Medical College of Thomas Jefferson University
Philadelphia, Pennsylvania
Independent Clinical Reviewer
Henny Heisler Billett, MD
Professor of Clinical Medicine
Department of Medicine/Hematology
Professor of Clinical Pathology
Department of Pathology
Montefiore Medical Center
Bronx, New York
Financial Disclosure and Conflicts of Interest
According to the disclosure policy of the University of Cincinnati and Princeton CME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of the University of Cincinnati and Princeton CME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The faculty has reported the following:
Dr. Billet disclosed no relevant financial relationships with any commercial interests.
Dr. Merli: Consultant—Bacchus, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, sanofi-aventis; Speaker’s Bureau—Boehringer Ingelheim, sanofi-aventis; Research Grant—Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, sanofi-aventis.
Planning Committee Kay Weigand, University of Cincinnati; Randy Robbin and John Savage, Princeton CME; Mary Johnson, Princeton Media Communications have disclosed no relevant financial relationships with any commercial interests.
The University of Cincinnati and Princeton CME require faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentation.
The faculty has disclosed that no off-label/unapproved uses of drugs or devices will be discussed.
Some of the clinical studies discussed in this activity may have been funded by manufacturers of drugs or devices.
